Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 7.57%.

  • Akebia Therapeutics' EBIT Margin rose 409800.0% to 7.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.88%, marking a year-over-year decrease of 2280900.0%. This contributed to the annual value of 31.51% for FY2024, which is 4310500.0% up from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' EBIT Margin is 7.57%, which was up 409800.0% from 22.55% recorded in Q2 2025.
  • Akebia Therapeutics' EBIT Margin's 5-year high stood at 26.97% during Q2 2022, with a 5-year trough of 149.95% in Q2 2021.
  • For the 5-year period, Akebia Therapeutics' EBIT Margin averaged around 48.28%, with its median value being 31.0% (2023).
  • Within the past 5 years, the most significant YoY rise in Akebia Therapeutics' EBIT Margin was 2747300bps (2021), while the steepest drop was -573300bps (2021).
  • Akebia Therapeutics' EBIT Margin (Quarter) stood at 113.28% in 2021, then surged by 92bps to 8.73% in 2022, then surged by 88bps to 1.07% in 2023, then crashed by -2776bps to 30.77% in 2024, then surged by 125bps to 7.57% in 2025.
  • Its EBIT Margin stands at 7.57% for Q3 2025, versus 22.55% for Q2 2025 and 23.57% for Q1 2025.